Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v4-EN
Language French English
Date Updated 2018-10-11 2018-10-11
Drug Identification Number 02443120 02443120
Brand name ACT OLMESARTAN HCT ACT OLMESARTAN HCT
Common or Proper name OLMESARTAN HCT OLMESARTAN HCT
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients HYDROCHLOROTHIAZIDE OLMESARTAN MEDOXOMIL HYDROCHLOROTHIAZIDE OLMESARTAN MEDOXOMIL
Strength(s) 12.5MG 40MG 12.5MG 40MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 30 30
ATC code C09DA C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2018-09-12 2018-09-12
Estimated end date 2019-01-06 2019-01-06
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments